MURPHY ANDREW J
Co-Chief Scientific Officer
MURPHY ANDREW J has filed 4 SEC Form 4 filings (35 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Oct 15, 2026.
On the most recent filing, MURPHY ANDREW J is listed as Co-Chief Scientific Officer at REGENERON PHARMACEUTICALS, INC. Inside the rolling window, MURPHY ANDREW J reported no open-market purchases and 1 open-market sale totaling $3.2M in REGN.
Companies traded
Other insiders at REGN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.2M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has MURPHY ANDREW J made?
MURPHY ANDREW J has filed 4 SEC Form 4 filings (35 transaction rows) across 1 company since 2025.
Which companies does MURPHY ANDREW J trade?
MURPHY ANDREW J has filed SEC Form 4 disclosures for 1 company, including REGN.
When was MURPHY ANDREW J's most recent SEC Form 4 filing?
MURPHY ANDREW J's most recent SEC Form 4 filing on Tracefour is dated Oct 15, 2026.
What is MURPHY ANDREW J's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, MURPHY ANDREW J is listed as Co-Chief Scientific Officer.
What is MURPHY ANDREW J's total buy and sell value in the current window?
Inside the rolling retention window, MURPHY ANDREW J bought $0 and sold $3.2M based on SEC Form 4 filings.
What was MURPHY ANDREW J's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 4,147 REGN shares on 2026-10-14, worth $3.2M, per SEC Form 4 filings.